Acute on Chronic Liver Failure
Conditions
Keywords
ACLF, Hepastem, HALPC
Brief summary
This is an interventional, double blind, randomized (2:1), and placebo-controlled study of 2 infusions of a 1 dose regimen of HepaStem in patients recently diagnosed (≤1 week) with ACLF grade 1 or 2 on top of Standard of Care (SoC), and for whom the diagnosis is not resolved on the day of infusion.
Interventions
DRUGHepaStem
HepaStem will be administered as an intravenous (IV) infusion
DRUGPlacebo
Placebo will be administered as an intravenous (IV) infusion
Sponsors
Cellaion SA
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Are adults aged between 18 and 75 years old. 2. Have an initial diagnosis of ACLF at the investigational site. 3. Have ACLF grade 1 or 2 according to the EASL-CLIF Consortium definition. 4. Have a total bilirubin ≥ 5 mg/dL. 5. Are able to read, understand and give written informed consent. Main
Exclusion criteria
1. Have a MELD-Na score \> 35. 2. Have underlying cirrhosis due to biliary disease. 3. Have underlying cirrhosis due to autoimmune hepatitis. 4. Have active bleeding at a non-compressible site or at a compressible site that, in the opinion of the investigator, poses an unacceptable risk for the patient's participation in the study. 5. Have received treatment for bleeding complications during the current hospitalization and has a persistent high risk for re-bleeding that, in the opinion of the investigator, poses an unacceptable risk for the patient's participation in the study. 6. Have a complete portal vein thrombosis. 7. Have coagulation disturbances defined as: * fibrinogen \< 80 mg/dL * platelets \< 50 x 10³/mm³ 8. Are requiring chronic dialysis therapy. 9. Have had a cerebrovascular, myocardial, limb arterial thrombotic event, or history for both thrombotic and hemorrhagic cerebrovascular events within 12 months prior to the Screening and not considered stabilized by the investigator. 10. Have a previous history of myocardial infarction and/or cardiac failure, with an ejection fraction rate (EFR) ≤ 40%.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Survival | Day 90 | Whether the patients are still alive will be recorded up to Day 90. Time and reason of death will be recorded. |
Secondary
| Measure | Time frame |
|---|---|
| Liver transplant-free survival | Day 90 |
| Transplant-free survival while free of ACLF | Day 90 |
| Transplant-free survival with MELD-Na score < 15 | Day 90 |
| Duration of overall hospitalization and hospitalization in ICU and non-ICU during the index hospitalization | up to Day 90 |
Countries
Austria, Belgium, Bulgaria, Denmark, Estonia, France, Germany, Italy, Latvia, Lithuania, North Macedonia, Poland, Slovakia, Spain
Outcome results
None listed